BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that data from its brentuximab vedotin (ADCETRIS™) and SGN-75 programs will be reported at the upcoming American Society of Clinical Oncology (ASCO) 2011 Annual Meeting being held June 3-7, 2011 in Chicago, IL. A summary of the company’s ASCO poster presentations is below and full abstracts can be accessed on the ASCO website at www.asco.org.
